Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double‐blind, placebo‐controlled study

2007255 citationsJournal Article

Authors

R. Lambert · University of Alberta

David Salonen · University of Toronto

Proton Rahman · St. John's University

Robert D. Inman · University of Toronto

Robert Wong · Reckitt Benckiser (United States)

Steven Einstein · BioClinica (United States)

G. T. D. Thomson ·

Abstract

Adalimumab significantly reduced both spinal and SI joint inflammation in patients with active AS after 12 weeks of treatment, and these improvements were maintained for up to 52 weeks.

Topics & Keywords

Spondyloarthritis Studies and Treatments Autoimmune and Inflammatory Disorders Research Inflammasome and immune disorders

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Arthritis & Rheumatism

Volume 56, Issue 12, pp. 4005-4014

DOI: 10.1002/art.23044

Field-Weighted Citation Impact: 12.71